<DOC>
	<DOCNO>NCT00321061</DOCNO>
	<brief_summary>This study test whether vaccination schedule experimental HIV vaccine safe whether cause side effect healthy adult volunteer . It also compare effect vaccine inject muscle ( intramuscular ) , skin ( subcutaneous ) , skin ( intradermal ) monitor social impact HIV vaccine study . Healthy volunteer 18-50 year old may eligible 42-week study . Participants screen antibody adenovirus , common virus cause upper respiratory infection , common cold . Half participant select positive half negative antibody virus . The vaccine use study know VRC-HIVDNA016-00-VP ( call `` DNA vaccine '' ) VRC-HIVADV014-00-VP ( call `` rAd5 vaccine '' ) . The DNA vaccine cod four HIV protein . The rAd5 vaccine make use adenovirus modify contain DNA cod three HIV protein . These vaccine cause HIV adenoviral infection . Participants randomly assign one six possible vaccination schedule include `` prime '' `` booster '' vaccine . The first vaccination prime immune system immune response boost later . The group differ type vaccine give ( DNA vaccine prime rAd5 booster rAd5 prime rAd5 booster ) , vaccine administer ( intramuscularly , subcutaneously intradermally ) schedule administration . All shot give upper arm . Subjects fill diary card home 5 day vaccination , record temperature symptom . The card turn clinic first visit 5 day complete . Subjects return clinic visit 3 day prime vaccination either come call clinic 7 day injection . They call study nurse 1 2 day booster vaccination . Participants 15-20 clinic visit course study , depend vaccination schedule . At visit , check health change problem , ask feeling take medication treatment , include over-the-counter medicine , herbal supplement , etc . Blood urine sample collect visit . Subjects test HIV several time ask question sexual behavior drug use . Throughout stu ...</brief_summary>
	<brief_title>Phase I Study Vaccination Schedule Experimental HIV Vaccines</brief_title>
	<detailed_description>STUDY DESIGN : The VRC DNA vaccine VRC recombinant adenoviral vector ( rAd5 ) vaccine previously show elicit immune response HIV-1-specific peptide administer intramuscularly ( IM ) alone prime-boost schedule . This Phase I , randomize , open-label exploratory study evaluate safety tolerability immune response IM , subcutaneous ( SC ) intradermal ( ID ) rout administration use prim vaccination prime-boost schedule . The randomization ensure subject negative positive screen adenovirus type 5 antibody ( Ad5Ab ) titer equally represent prime-boost schedule evaluate study . Group 1 subject receive three DNA prime vaccination follow rAd5 boost vaccination Group 2 subject receive one rAd5 prime vaccination follow rAd5 boost vaccination . It also interest explore whether vaccination SC ID route alters functional quality immune response . About half subject screen HIV vaccine study VRC Clinic negative Ad5Ab titer half positive Ad5Ab titer . The hypothesis : 1 ) IM , SC ID safe route administration DNA rAd5 vaccine ; 2 ) regimens elicit immune response HIV-1-specific peptide ; 3 ) intradermal administration allow low dosage DNA vaccine use elicit immune response ; 4 ) rAd5 booster administer rAd5 prime boost cellular humoral immune response . The primary objective relate evaluation safety tolerability DNA rAd5 vaccine administer IM , SC ID route . Secondary objective related evaluation immunogenicity vaccine administer SC ID route compare IM route social impact participate HIV-1 vaccine trial . Exploratory evaluation immunogenicity vaccination regimen also plan . PROTOCOL DESCRIPTION : VRC-HIVDNA016-00-VP ( DNA vaccine ) compose 6 close , circular DNA plasmid encode HIV-1 Gag , Pol Nef ( clade B ) Env glycoprotein clade A , clade B , clade C ; plasmid comprise 16.67 percent ( weight ) vaccine . VRC-HIVADV014-00-VP ( rAd5 vaccine ) compose 4 recombinant non-replicating adenoviral vector encode HIV-1 Gag/Pol polyproteins ( clade B ) Env glycoprotein clade A , clade B , clade C , combine 3:1:1:1 ratio , respectively . SUBJECTS : Sixty healthy adult volunteer , 18 50 year old , 30 subject negative Ad5Ab titer ( less 1:12 ) 30 subject positive Ad5Ab titer ( great equal 1:12 ) . STUDY PLAN : Subjects negative positive Ad5Ab titer equally randomize six prime-boost schedule evaluate study show schema . All injection administer needle syringe device appropriate route administration specify .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>INCLUSION CRITERIA : A participant must meet following criterion : 1 . 18 50 year old . 2 . Available clinical followup Week 42 study . 3 . Able provide proof identity satisfaction study clinician complete enrollment process . 4 . Complete Assessment Understanding prior enrollment verbalize understanding question answer incorrectly . 5 . Able willing complete inform consent process . 6 . Willing receive HIV test result willing abide NIH guideline partner notification positive HIV result . 7 . Willing donate blood sample storage use future research . 8 . Willing discuss HIV infection risk amenable risk reduction counsel . 9 . In good general health without clinically significant medical history . 10 . Physical examination laboratory result without clinically significant finding body mass index ( BMI ) less 40 within 28 day prior enrollment . Laboratory Criteria within 28 day prior enrollment : 11 . Hemoglobin great equal 11.5 g/dL woman ; great equal 13.5 g/dL men . 12 . White blood cell ( WBC ) = 3,30012,000 cells/mm ( 3 ) . 13 . Differential either within institutional normal range accompany site physician approval . 14 . Total lymphocyte count great equal 800 cells/mm3 . 15 . Platelets equal 125,000 550,000/mm ( 3 ) . 16 . Alanine aminotransferase ( ALT ) less equal 1.25 x upper limit normal . 17 . Serum creatinine less equal upper limit normal . 18 . Normal urinalysis define negative glucose , negative trace protein , clinically significant blood urine . 19 . Negative Food Drug Administration ( FDA ) approve HIV blood test . 20 . Negative hepatitis B surface antigen . 21 . Negative antiHCV ( hepatitis C virus antibody ) negative HCV PCR . FemaleSpecific Criteria : 22 . Negative betaHCG ( human chorionic gonadotropin ) pregnancy test ( urine serum ) day enrollment woman presume reproductive potential . 23 . A female participant must meet following criterion : No reproductive potential menopause [ one year without menses ] hysterectomy , bilateral oophorectomy , tubal ligation , Or Participant agree heterosexually inactive least 21 day prior enrollment Week 42 study , Or Participant agree consistently practice contraception least 21 day prior enrollment Week 42 study one follow method : condom , male female , without spermicide diaphragm cervical cap spermicide intrauterine device contraceptive pill patch , Norplant , DepoProvera FDAapproved contraceptive method male partner previously undergone vasectomy . EXCLUSION CRITERIA : A volunteer exclude one follow condition apply : Women : 1 . Woman breastfeed plan become pregnant 42 week study participation . Volunteer receive following substance : 2 . HIV vaccine prior clinical trial . 3 . Immunosuppressive medication cytotoxic medication inhale corticosteroid within past 3 month ( exception corticosteroid nasal spray allergic rhinitis ; topical corticosteroid acute uncomplicated dermatitis , shortacting betaagonists control asthmatic ; course corticosteroid 10 day few duration complete least 2 week prior study enrollment nonchronic condition ) . 4 . Blood product within 120 day prior HIV screen . 5 . Immunoglobulin within 60 day prior HIV screen . 6 . Investigational research agent within 30 day prior initial study vaccine administration . 7 . Live attenuate vaccine within 30 day prior initial study vaccine administration . 8 . Medically indicated subunit kill vaccine , e.g . influenza , pneumococcal , allergy treatment antigen injection , within 14 day study vaccine administration . 9 . Current antituberculosis prophylaxis therapy . Volunteer history follow clinically significant condition : 10 . Serious adverse reaction vaccine anaphylaxis , hive , respiratory difficulty , angioedema , abdominal pain . 11 . Autoimmune disease immunodeficiency 12 . Asthma unstable require emergent care , urgent care , hospitalization intubation past two year require use oral intravenous corticosteroid . 13 . Diabetes mellitus ( type I II ) , exception gestational diabetes . 14 . History thyroidectomy thyroid disease require medication within past 12 month . 15 . Serious angioedema episode within previous 3 year require medication previous two year . 16 . Hypertension well control medication 145/95 enrollment . 17 . Bleeding disorder diagnose doctor ( e.g . factor deficiency , coagulopathy , platelet disorder require special precaution ) significant bruise bleed difficulty IM injection blood draw . 18 . Syphilis infection active positive serology due syphilis infection treat less six month ago . 19 . Malignancy active treat malignancy reasonable assurance sustain cure malignancy likely recur period study . 20 . Seizure disorder : 1 ) febrile seizure age two , 2 ) seizure secondary alcohol withdrawal 3 year ago , 3 ) singular seizure require treatment within last 3 year . 21 . Asplenia , functional asplenia condition result absence removal spleen . 22 . Psychiatric condition precludes compliance protocol ; past present psychosis ; past present bipolar disorder ; disorder require lithium ; within five year prior enrollment , history suicide plan attempt . 23 . Any medical , psychiatric , social condition , occupational reason responsibility , judgment investigator , contraindication protocol participation impair volunteer 's ability give inform consent . 24 . A subject 3 5 health risk factor note exclude : Current smoker ( quit smoking less 28 day prior enrollment ) BMI great 35 Fasting low density lipoprotein ( LDL ) great 159 mg/dL fast cholesterol great 239 mg/dL Systolic blood pressure great 140 mm Hg diastolic blood pressure great 90 mm Hg Fasting blood glucose great 125 mg/dL Note : The fast blood test require 8 hour fast prior blood draw . The result use eligibility screening must test complete 12 week ( 84 day ) prior day enrollment . The individual criterion BMI ( inclusion item 10 ) blood pressure ( exclusion item 16 ) must also meet .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2, 2009</verification_date>
	<keyword>HIV Negative</keyword>
	<keyword>Healthy</keyword>
	<keyword>Immunity</keyword>
	<keyword>Preventive</keyword>
	<keyword>Virus</keyword>
	<keyword>Healthy Volunteer</keyword>
	<keyword>HV</keyword>
</DOC>